Quantum-Si Incorporated

Quantum-Si Incorporated is a life sciences company dedicated to revolutionizing proteomics through advanced research and analytical technologies. Founded in 2013, the company's core mission is to democratize access to single-molecule protein analysis, making next-generation protein sequencing (NGPS) available to every laboratory. Quantum-Si's headquarters are located in Branford, Connecticut.

The company offers a comprehensive suite of products, including its flagship Platinum and Platinum Pro NGPS instruments, which are benchtop systems designed for single-molecule, amino acid-level resolution protein sequencing. Complementing these instruments are various consumables such as library preparation kits, sequencing kits (including the V4 Sequencing Kit), and barcoding kits. Quantum-Si also provides the Platinum analysis software, a cloud-based solution that automates data analysis and visualization, thereby accelerating proteomic discoveries in areas like drug development, diagnostics, and scientific research.

Led by President and CEO Jeff Hawkins, with founder Dr. Jonathan Rothberg serving on the board, Quantum-Si continues to advance its technology. Recent developments include the successful demonstration of sequencing on integrated Proteus instruments in April 2026 and the launch of a multi-city roadshow for its Proteus platform. The company also reported its fourth-quarter and full-year 2025 financial results in March 2026 and announced a new manuscript in April 2026 highlighting the value of single-molecule protein sequencing for identifying cancer treatment strategies. Quantum-Si aims to pioneer the post-genomic era by providing unparalleled resolution and functional insights into proteins.

Latest updates

Quantum-Si to Present at BioConnect Conference Amidst Proteomics Investment Scrutiny

Event summary

  • Quantum-Si (QSI) will participate in the H.C. Wainwright BioConnect Investor Conference on May 19, 2026.
  • CEO Jeff Hawkins and CFO Jeff Keyes will conduct one-on-one meetings with investors.
  • Hawkins will deliver a fireside chat at 4:00 PM ET on May 19, 2026, with a live webcast available.
  • The conference is located at 151 West 42nd Street, New York, NY.

The big picture

Quantum-Si’s participation in the BioConnect conference highlights the ongoing investor interest in proteomics, a field experiencing increased attention due to its potential to revolutionize drug discovery and diagnostics. However, proteomics companies face significant challenges in achieving widespread adoption and demonstrating a clear return on investment, particularly as capital markets tighten. The conference provides a key opportunity for Quantum-Si to articulate its value proposition and address investor concerns.

What we're watching

Investor Sentiment
The conference appearance will be a key test of investor confidence given the capital-intensive nature of proteomics platform development and the current macroeconomic climate.
Technology Adoption
The success of Quantum-Si’s platform hinges on its ability to displace established, multistep workflows; the fireside chat should reveal progress on adoption rates within research labs.
Competitive Landscape
Increased scrutiny of proteomics companies may intensify competition, and Quantum-Si’s ability to demonstrate a clear technological advantage will be crucial for maintaining market share.

Quantum-Si Demonstrates Automated Protein Sequencing Workflow

Event summary

  • Quantum-Si achieved a fully automated protein sequencing workflow on integrated Proteus instruments using a developmental KinetIQ Array.
  • The KinetIQ Array now detects 17 amino acids, a four-month improvement from detecting 15 in December 2025.
  • The demonstration involved a user-initiated process, with the instrument handling sample loading and data acquisition.
  • Quantum-Si anticipates early access customers will have hands-on experience with the technology this summer.

The big picture

Quantum-Si's demonstration of a fully automated protein sequencing workflow represents a significant step towards commercializing its Proteus platform, which aims to disrupt the proteomics market. The rapid improvement in amino acid detection (adding two new amino acids in four months) suggests a potentially accelerated development cycle, but also highlights the challenges of scaling a complex technology. The company's success hinges on its ability to ramp up manufacturing and secure widespread adoption among researchers.

What we're watching

Manufacturing Scale
The ability to rapidly expand Proteus instrument production will be critical to meeting anticipated demand and achieving commercial launch by the end of 2026, given the reliance on manufacturing partners.
Customer Adoption
Early access customer feedback and adoption rates will be a key indicator of the technology's utility and potential for broader market penetration beyond the initial user group.
Competitive Landscape
The pace at which competitors develop and deploy similar automated protein sequencing solutions will determine Quantum-Si's long-term market share and pricing power.
CID: 1999